Last Updated : March 18, 2016
Details
FilesGeneric Name:
Ruxolitinib
Project Status:
Complete
Therapeutic Area:
Polycythemia vera
Manufacturer:
Novartis Pharmaceuticals Canada Inc.
Brand Name:
Jakavi
Project Line:
Reimbursement Review
Project Number:
PC0065-000
NOC Status at Filing:
Pre NOC
Strength:
5 mg, 10 mg, 15 mg, 20 mg tablets
Tumour Type:
Other
Indications:
Polycythemia vera
Funding Request:
For the treatment of adult patients with polycythemia vera who are resistant to or intolerant of hydroxyurea
Pre Noc Submission:
Yes
Sponsor:
Novartis Pharmaceuticals Canada Inc.
Submission Date:
Submission Deemed Complete:
Prioritization Requested:
Not Requested
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommendation Type:
Reimburse with clinical criteria and/or conditions
pERC Meeting:
Final Recommendation Issued:
Files
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.
Last Updated : March 18, 2016